|
1）日本膵臓学会．膵癌登録報告2007．膵臓．2007; 22: e1-429
|
|
|
|
2）Burris HA, 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997; 15: 2403-13
|
|
|
|
|
3）Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007; 25: 1960-6
|
|
|
|
|
|
4）Vaccaro V, Sperduti I, Milella M. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011; 365: 768-9; author reply 769
|
|
|
|
|
|
5）Rosenberg SA, Lotze MT, Yang JC, et al. Prospective randomized trial of high-dose inter-leukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst. 1993; 85: 622-32
|
|
|
|
|
|
6）Tani M, Tanimura H, Yamaue H, et al. In vitro generation of activated natural killer cells and cytotoxic macrophages with lentinan. Eur J Clin Pharmacol. 1992; 42: 623-7
|
|
|
|
|
|
7）Yamaue H, Tanimura H, Iwahashi M, et al. Role of interleukin-2 and interferon-gamma in induction of activated natural killer cells from mice primed in vivo and subsequently challenged in vitro with the streptococcal preparation OK432. Cancer Immunol Immunother. 1989; 29: 79-86
|
|
|
|
|
|
8）Tani M, Tanimura H, Yamaue H, et al. Generation of CD4+ cytotoxic T lymphocytes stimulated by immobilized anti-CD3 monoclonal antibody and interleukin-2 in cancer patients. Int J Cancer. 1995; 60: 802-7
|
|
|
|
|
|
9）Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science. 1986; 233: 1318-21
|
|
|
|
|
|
10）van der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 1991; 254: 1643-7
|
|
|
|
|
|
11）Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med. 2004; 10: 909-15
|
|
|
|
|
|
12）Schlom J, Therapeutic cancer vaccines: current status and moving forward. J Natl Cancer Inst. 2012; 104: 599-613
|
|
|
|
|
|
13）Khong HT, Restifo NP. Natural selection of tumor variants in the generation of “tumor escape” phenotypes. Nat Immunol. 2002; 3: 999-1005
|
|
|
|
|
|
14）Ryschich E, Notzel T, Hinz U, et al. Control of T-cell-mediated immune response by HLA class I in human pancreatic carcinoma. Clin Cancer Res. 2005; 11: 498-504
|
|
|
|
|
|
15）Marincola FM, Jaffee EM, Hicklin DJ, et al. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol. 2000; 74: 181-273
|
|
|
|
|
|
16）Garrido F, Algarra I, Garcia-Lora AM. The escape of cancer from T lymphocytes: immunoselection of MHC class I loss variants harboring structural-irreversible “hard” lesions. Cancer Immunol Immunother. 2010; 59: 1601-6
|
|
|
|
|
|
17）Ishigami S, Natsugoe S, Nakajo A, et al. HLA-class I expression in gastric cancer. J Surg Oncol. 2008; 97: 605-8
|
|
|
|
|
|
18）Tsukahara T, Kawaguchi S, Torigoe T, et al. Prognostic significance of HLA class I expression in osteosarcoma defined by anti-pan HLA class I monoclonal antibody, EMR8-5. Cancer Sci. 2006; 97: 1374-80
|
|
|
|
|
19）Kitamura H, Torigoe T, Asanuma H, et al. Down-regulation of HLA class I antigens in prostate cancer tissues and up-regulation by histone deacetylase inhibition. J Urol. 2007; 178: 692-6
|
|
|
|
|
|
20）Teicher BA. Transforming growth factor-beta and the immune response to malignant disease. Clin Cancer Res. 2007; 13: 6247-51
|
|
|
|
|
|
21）Ichihara F, Kono K, Takahashi A, et al. In-creased populations of regulatory T cells in peri-pheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin Cancer Res. 2003; 9: 4404-8
|
|
|
|
|
|
22）Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995; 1: 27-31
|
|
|
|
|
|
23）Li Y, Wang MN, Li H, et al. Active immunization against the vascular endothelial growth factor receptor flk1 inhibits tumor angiogenesis and metastasis. J Exp Med. 2002; 195: 1575-84
|
|
|
|
|
|
24）Wada S, Tsunoda T, Baba T, et al. Rationale for antiangiogenic cancer therapy with vaccination using epitope peptides derived from human vascular endothelial growth factor receptor 2. Cancer Res. 2005; 65: 4939-46
|
|
|
|
|
|
25）Ishizaki H, Tsunoda T, Wada S, et al. Inhibition of tumor growth with antiangiogenic cancer vaccine using epitope peptides derived from human vascular endothelial growth factor receptor 1. Clin Cancer Res. 2006; 12: 5841-9
|
|
|
|
|
|
26）Itakura J, Ishiwata T, Friess H, et al. Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression. Clin Cancer Res. 1997; 3: 1309-16
|
|
|
|
|
|
27）Seo Y, Baba H, Fukuda T, et al. High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma. Cancer. 2000; 88: 2239-45
|
|
|
|
|
|
28）Noguchi K, Tanimura H, Yamaue H, et al. Cisplatin modulates tumor cell susceptibility to tumor-infiltrating lymphocytes in vivo. Oncol Rep. 1997; 4: 927-30
|
|
|
|
|
|
29）Noguchi K, Tanimura H, Yamaue H, et al. Enhancement of tumor cell susceptibility to tumor-infiltrating lymphocytes by cisplatin. J Cancer Res Clin Oncol. 1997; 123: 345-51
|
|
|
|
|
|
30）Suzuki E, Kapoor V, Jassar AS, et al. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res. 2005; 11: 6713-21
|
|
|
|
|
|
31）Plate JM, Plate AE, Shott S, et al. Effect of gemcitabine on immune cells in subjects with adenocarcinoma of the pancreas. Cancer Immunol Immunother. 2005; 54: 915-25
|
|
|
|
|
|
32）Miyazawa M, Ohsawa R, Tsunoda T, et al. Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer. Cancer Sci. 2010; 101: 433-9
|
|
|
|
|
|
33）Imai K, Hirata S, Irie A, et al. Identification of HLA-A2-restricted CTL epitopes of a novel tumour-associated antigen, KIF20A, over-expressed in pancreatic cancer. Br J Cancer. 2011; 104: 300-7
|
|
|
|
|
|
34）Osawa R, Tsunoda T, Yoshimura S, et al. Identification of HLA-A24-Restricted Novel T Cell Epitope Peptides Derived from P-Cadherin and Kinesin Family Member 20A. J Biomed Biotechnol. 2012: 848042. [Epub 2012 Jun 19]
|
|
|
|
|
|
35）Okuno K, Sugiura F, Hida J, et al. [Preliminary study of Peptide vaccine with UFT/LV as adjuvant setting for stage III colorectal cancer]. Gan To Kagaku Ryoho. 2011; 38: 1906-8
|
|
|
|
|
|
36）Kono K, Iinuma H, Akutsu Y, et al. Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens. J Transl Med. 2012; 10: 141
|
|
|
|
|
|
37）Butterfield LH, Palucka AK, Britten CM, et al. Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers. Clin Cancer Res. 2011; 17: 3064-76
|
|
|
|
|
|
38）Disis ML. Immunologic biomarkers as correlates of clinical response to cancer immunotherapy. Cancer Immunol Immunother. 2011; 60: 433-42
|
|
|
|
|
|
39）Katsuda M, Iwahashi M, Matsuda K, et al. Comparison of different classes of CpG-ODN in augmenting the generation of human epitope peptide-specific CTLs. Int J Oncol. 2011; 39: 1295-302
|
|
|
|
|
|
40）Iwahashi M, Katsuda M, Nakamori M, et al. Vaccination with peptides derived from cancer-testis antigens in combination with CpG-7909 elicits strong specific CD8+ T cell response in patients with metastatic esophageal squamous cell carcinoma. Cancer Sci. 2010; 101: 2510-7
|
|
|
|
|
|
41）Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010; 363: 411-22
|
|
|
|
|